GERMANTOWN, Maryland, and HILDEN, Germany, December 12, 2016 /PRNewswire/ --
QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today welcomed new evidence-based guidelines for TB screening that have broadened the preferential recommendation for the use of modern blood-based TB tests (tests based on interferon gamma release, or IGRAs) over the 100-year-old tuberculin skin test (TST) in a wider group of people at risk for latent or active tuberculosis infection.
QIAGEN's QuantiFERON-TB® Gold (QFT®) is the leading IGRA in the U.S. and worldwide, with more than five million tests sold in the U.S. during the last year and seven-fold the volume of other IGRAs. This expanded preferential recommendation is expected to drive more rapid conversion from the use of the TST given that these guidelines are the first of their kind to recommend IGRAs over the TST based on disease progression risk, and not just based on patient types.
The new guidelines were the outcome of a task force supported by the American Thoracic Society (ATS), the U.S. Centers for Disease Control and Prevention (CDC), and the Infectious Diseases Society of America, and were published in the latest issue of Clinical Infectious Diseases. The updated guidelines on TB, a potentially lethal but preventable disease, were also endorsed by the European Respiratory Society.
Click here for the full press release
SOURCE QIAGEN N.V.